Ilant Health, a company focused on value-based obesity and cardiometabolic care, has closed a $15 million Series A financing round led by Cornucopian Capital. The round included participation from naturalX, Peakbridge, Semcap AI, Evidenced, Operator Partners, and existing investors Celtic, LifeX, and AlphaLab, bringing the company’s total funding to more than $22 million.
The financing comes as employers and health plans continue to face rising costs associated with GLP-1 weight-loss therapies. Increasing demand for these medications has created financial pressure for self-insured employers and benefit managers seeking to balance access to treatment with long-term healthcare spending.
Founded by former McKinsey consultant and Molina Healthcare executive Elina Onitskansky, Ilant Health has positioned itself as an integrated obesity management platform designed to move beyond medication-centric approaches. The company’s model evaluates patients using clinical, behavioral and personal health data to create individualized treatment pathways.
These care plans may include behavioral therapy, metabolic medications, nutrition support, physical activity programs, stress management interventions and, when appropriate, bariatric surgery options. The company uses analytics to identify which interventions are most likely to be effective for individual patients, with the goal of improving outcomes while reducing unnecessary healthcare spending.
According to Ilant, members enrolled in its programs have achieved an average weight loss of 15%, compared with a reported real-world benchmark of 5.8% associated with less coordinated treatment approaches. The company also reports improvements in broader measures of wellbeing, including an average increase of two self-reported mentally healthy days per month.
Aryeh Ganz, Founder and Managing Partner of Cornucopian Capital, said the future of digital health will be defined by organizations that provide “outcomes as a service” rather than simply offering technology tools or medication access. He noted that long-term success in cardiometabolic care will depend on aligning clinical outcomes with measurable economic value.
A key component of Ilant’s strategy is its direct contracting approach with pharmaceutical manufacturers. In late 2025, the company established transparent pricing arrangements for obesity medications through Eli Lilly’s Employer Connect program and also developed operational collaborations with Novo Nordisk.
These relationships are intended to provide employers and health plans with greater visibility into pharmacy spending and more predictable pricing structures. By combining population health analytics with targeted treatment recommendations, Ilant aims to help benefit managers identify members most likely to benefit from specific therapies while improving both clinical outcomes and return on investment.
Click here for the original news story.
